Acquired by Regeneron Pharmaceuticals in May 2022
CMPI - Checkmate Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
CMPI price evolution
CMPI
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $39.5 | $50.7 | $53.51 | $63.13 |
| Short term investments | $20.55 | $20.19 | $27.35 | $22.24 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $62.11 | $73.96 | $88.67 | $91.07 |
| Long term investments | $10.24 | |||
| Property, plant & equipment | $0.73 | $0.78 | $0.67 | $0.37 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $4.83 | $4.88 | $0.67 | $10.61 |
| Total investments | $20.55 | $20.19 | $27.35 | $32.48 |
| Total assets | $66.94 | $78.84 | $89.34 | $101.68 |
| Current liabilities | ||||
| Accounts payable | $3.61 | $3.38 | $2.52 | $2.2 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $11.94 | $9.38 | $7.81 | $6.7 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $11.94 | $9.38 | $7.81 | $6.7 |
| Shareholders' equity | ||||
| Retained earnings | -$217.34 | -$201.48 | -$188.13 | -$173.17 |
| Other shareholder equity | -$0.06 | -$0.01 | -$0 | -$0.03 |
| Total shareholder equity | $55 | $69.46 | $81.53 | $94.98 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $50.7 | $43.08 | $4.21 | $12.06 |
| Short term investments | $20.19 | $51.83 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $73.96 | $102.1 | $5.13 | $12.49 |
| Long term investments | $30.97 | |||
| Property, plant & equipment | $0.78 | |||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $4.88 | $30.97 | ||
| Total investments | $20.19 | $82.8 | ||
| Total assets | $78.84 | $133.07 | $5.13 | $12.49 |
| Current liabilities | ||||
| Accounts payable | $3.38 | $2.3 | $2.23 | $1.63 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $9.38 | $7.88 | $5.63 | $3.32 |
| Long term debt | ||||
| Total noncurrent liabilities | $96.93 | $71.97 | ||
| Total debt | ||||
| Total liabilities | $9.38 | $7.88 | $5.63 | $3.32 |
| Shareholders' equity | ||||
| Retained earnings | -$201.48 | -$140.07 | -$97.44 | -$62.8 |
| Other shareholder equity | -$0.01 | -$0.07 | ||
| Total shareholder equity | $69.46 | $125.2 | -$97.44 | $9.17 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $11.65 | $9.2 | $11.38 | $14.87 |
| Selling, general & administrative | $4.24 | $4.15 | $3.6 | $4.09 |
| Total operating expenses | $15.89 | $13.35 | $14.98 | $18.95 |
| Operating income | -$15.89 | -$13.35 | -$14.98 | -$18.95 |
| Income from continuing operations | ||||
| EBIT | -$15.87 | -$13.34 | -$14.97 | -$18.97 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$15.87 | -$13.34 | -$14.97 | -$18.97 |
| Income (for common shares) | -$15.87 | -$13.34 | -$14.97 | -$18.97 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $45.82 | $26.72 | $24.25 | $18.17 |
| Selling, general & administrative | $15.65 | $10.19 | $4.63 | $2.82 |
| Total operating expenses | $61.47 | $36.9 | $28.89 | $20.99 |
| Operating income | -$61.47 | -$36.9 | -$28.89 | -$20.99 |
| Income from continuing operations | ||||
| EBIT | -$61.41 | -$36.91 | -$28.29 | -$20.99 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$61.41 | -$36.91 | -$28.29 | -$20.81 |
| Income (for common shares) | -$61.41 | -$42.91 | -$35.04 | -$25.13 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Net income | -$15.87 | -$13.34 | -$14.97 | -$18.97 |
| Operating activities | ||||
| Depreciation | $0.04 | $0.06 | $0.01 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.45 | $1.28 | $1.48 | $1.49 |
| Total cash flows from operations | -$10.67 | -$10 | -$14.02 | -$15.39 |
| Investing activities | ||||
| Capital expenditures | -$0.16 | -$0.3 | -$0.38 | |
| Investments | -$0.53 | $7.02 | $5.02 | $39.73 |
| Total cash flows from investing | -$0.53 | $6.85 | $4.72 | $39.36 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | $0 | $0.02 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.33 | -$0.31 | $0.02 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$11.2 | -$2.82 | -$9.62 | $23.98 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$61.41 | -$36.91 | -$28.29 | -$20.81 |
| Operating activities | ||||
| Depreciation | $0.07 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.46 | $2.04 | $0.34 | |
| Total cash flows from operations | -$53.72 | -$38.11 | -$26.85 | -$20.42 |
| Investing activities | ||||
| Capital expenditures | -$0.84 | |||
| Investments | $62.03 | -$83.29 | ||
| Total cash flows from investing | $61.19 | -$83.29 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.15 | $67.73 | $0.07 | $10.93 |
| Net borrowings | $10 | |||
| Total cash flows from financing | $0.15 | $160.27 | $18.98 | $10.93 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $7.62 | $38.87 | -$7.87 | -$9.49 |
News
|
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
Zacks via Yahoo Finance
1 Jun 2022
|
|
Regeneron Reports First Quarter 2022 Financial and Operating Results
WFMZ Eastern Pennsylvania and Western New Jersey
4 May 2022
|
|
April M&A Roundup: Solar energy, media tech and software
The Business Journals
3 May 2022
|
|
Merger Arbitrage Mondays - Blackstone Acquires American Campus Communities (NYSE:ACC)
Seeking Alpha
25 Apr 2022
|
|
Regeneron makes $250M bid to buy pharmaceuticals firm
Albany Times Union
20 Apr 2022
|
|
5 Outperforming Biotech Stocks with More Room to Run
Entrpreneur
20 Apr 2022
|
|
Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More
Zacks via Yahoo Finance
20 Apr 2022
|
|
54 Biggest Movers From Yesterday
Benzinga
20 Apr 2022
|
|
Regeneron to Acquire Checkmate Pharmaceuticals in $250m Deal By Investing.com
Investing.com
19 Apr 2022
|
|
38 Stocks Moving In Tuesday's Mid-Day Session
Benzinga
19 Apr 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 21.63M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$63.04M |
| EBIT | -$63.14M |
| Net Income | -$63.14M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 2.55 |
| Cash/Share | 1.83 |
| EPS | -$2.92 |
|---|---|
| ROA | -74.99% |
| ROE | -83.92% |
| Debt/Equity | 0.14 |
|---|---|
| Net debt/EBITDA | 0.44 |
| Current ratio | 5.20 |
| Quick ratio | 5.20 |